The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.
A study of Chinese healthcare workers may foreshadow the mental health burden placed upon physicians, nurses, and other professionals as COVID-19 strains the medical system in the United States.
The COVID-19 epidemic has underscored potential gaps in mental health services during emergencies, while also testing the resilience of healthcare workers and medical systems.
Overall, in all patients with MDD, sleep ultradian cycle number was positively associated with REMS percentage, REMS duration, and REMS/NREMS ratio and negatively associated with REM latency.
There is an emerging view that sleep disorders are not merely symptoms of psychiatric conditions; instead there may be a complex, bidirectional relationship between psychiatric and sleep disorders.
Self-monitoring behaviors may serve as a potential mediator of therapeutic change for patients with epilepsy.
The stresses and sleep disturbances of shift work can lead to major mental health issues, as well as workplace challenges, including safety concerns and poor on-the-job performance.
Women with insomnia were more likely to report prior or current depression than women without insomnia in the study.
A new guideline from AAN offers recommendations on the use of behavioral, nutraceutical, and complementary and alternative medicine (CAM) for improving sleep disorders in children with ASD.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
